Geranylgeranylacetone protects against myocardial ischemia and reperfusion injury by inhibiting high-mobility group box 1 protein in rats

NENG WANG, XINWEN MIN, DONGFENG LI, PEIGEN HE and LIBIN ZHAO

Department of Cardiology, Dongfeng Hospital of Hubei Medical University, Shiyan, Hubei 442008, P.R. China

Received September 9, 2011; Accepted October 31, 2011

DOI: 10.3892/mmr.2011.666

Abstract. The high mobility group box 1 (HMGB1) protein plays an important role in myocardial ischemia and reperfusion (I/R) injury. Geranylgeranylacetone (GGA), a heat shock protein 72 inducer, has been reported to reduce myocardial I/R injury. The aim of this study was to investigate the cardioprotective mechanism of GGA during myocardial I/R injury in rats. Anesthetized male rats were treated once with GGA (200 mg/kg, p.o.) 24 h before ischemia, and subjected to ischemia for 30 min, followed by reperfusion for 4 h. Lactate dehydrogenase (LDH), creatine kinase (CK), malondialdehyde (MDA), superoxide dismutase (SOD) activity and infarct size were measured. HMGB1 expression was assessed by immunoblotting. The results showed that pre-treatment with GGA (200 mg/kg) significantly reduced the infarct size and the levels of LDH and CK after 4 h of reperfusion (all P<0.05). GGA also significantly inhibited the increase in MDA levels and the decrease in SOD levels (both P<0.05). Meanwhile, GGA considerably suppressed the expression of HMGB1 induced by I/R. The present study suggests that GGA is capable of attenuating myocardial I/R injury by inhibiting HMGB1 expression.

Introduction

The high mobility group box 1 (HMGB1) protein is a nuclear protein released by necrotic, apoptotic or activated innate immune cells (such as macrophages and monocytes) (1,2), and serves as a novel pro-inflammatory cytokine in cardiovascular diseases (3-5). HMGB1 has recently been found to function as an early mediator of inflammation and cell injury during myocardial ischemia and reperfusion (I/R) as well as a classical early pro-inflammatory cytokine, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and may promote the release of TNF-α and IL-6. By contrast, HMGB1 A box peptide (a specific HMGB1 antagonist) reduces myocardial I/R injury and inhibits the release of TNF-α and IL-6 (6,7). These results suggest that HMGB1 plays a key role in myocardial I/R injury.

Geranylgeranylacetone (GGA), a heat shock protein 72 (HSP72) inducer, has been reported to reduce myocardial I/R injury (8,9). However, the cardioprotective mechanism of GGA during myocardial I/R remains unclear. We hypothesized that GGA may reduce myocardial I/R injury by inhibiting HMGB1 expression. The main aim of this study was to investigate whether GGA protects against myocardial I/R injury by inhibiting HMGB1 expression in a rat myocardial I/R model.

Materials and methods

Animal preparation. The experiment protocol conformed to the Guideline for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, revised 1996) and was approved by the Institutional Animal Care and Use Committee. Fifty male Sprague-Dawley rats (250-300 g) were randomly assigned into four groups receiving the following treatments: Group 1, sham operated control (SO) (n=10); rats were subjected to surgical manipulation without the induction of myocardial ischemia. Group 2, SO + GGA (SO-GGA) (n=10); rats were treated with GGA (200 mg/kg, p.o.; Sigma-Aldrich Co., St. Louis, MO, USA) (8) and then subjected to surgical manipulation without the induction of myocardial ischemia. Group 2, SO + GGA (SO-GGA) (n=10); rats were treated with GGA (200 mg/kg, p.o.; Sigma-Aldrich Co., St. Louis, MO, USA) (8) and then subjected to surgical manipulation without the induction of myocardial ischemia. GGA was dissolved in an emulsion with 5% gum arabic and 0.008% tocopherol. Group 3, ischemia and reperfusion (I/R) (n=15); rats were subjected to the left anterior descending coronary artery (LAD) occlusion for 30 min followed by reperfusion for 4 h. Group 4, GGA + I/R (GGA-I/R) (n=15); rats were treated with GGA (200 mg/kg, p.o.) 24 h prior to ischemia.

After being anesthetized with sodium pentobarbital (45 mg/kg, i.p.), the rats were ventilated artificially with a volume-controlled rodent respirator at 70 strokes per min. Rats were placed on an electric heating pad to maintain body temperature at 37˚C. Heparin (200 IU/kg, i.v.) was administered prior to ischemia. Lead-II of the electrocardiogram was monitored with subcutaneous stainless steel electrodes. The electrocardiogram was monitored using a computer-based EP system (LEAD2000B; Jinjiang Ltd., Chengdu, China).
A thoracotomy through a left parasternal incision was performed to expose the anterior wall of the left ventricle. A 4-0 silk suture on a small curved needle was passed through the myocardium beneath the middle segment of the LAD branch, coursing down the middle of the anterior wall of the left ventricle. A small vinyl flake was passed into both ends of the suture, which was then fixed by clamping the tube with a mosquito haemostat. A successful myocardial I/R model was confirmed by ST segment elevation in Leads-II and regional cyanosis of the myocardial surface. The rats underwent a 30-min occlusion of the LAD, followed by a 4-h reperfusion.

Assessment of myocardial injury. To assess the lactate dehydrogenase (LDH) and creatine kinase (CK) levels, blood samples were collected and centrifuged. Standard techniques using commercialized assay kits were used for analyses, according to the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Values were expressed in international units (IU) per liter.

Assessment of infarct size. Infarct size was established by 2,3,5-triphenyltetrazolium chloride staining (TTC; Sigma-Aldrich), as previously described (7). Briefly, after reperfusion the LAD was occluded again and 2 ml of 1.0% Evans blue dye was injected via the femoral vein. Each heart was then sliced horizontally to yield five slices. The slices were incubated in 1% TTC for 15 min at 37°C. The infarct area (white) and the area at risk (red and white) from each section were measured using an image analyser (Image-Pro Plus 3.0; Media Cybernetics, Silver Spring, MD, USA). Infarct size was expressed as a percentage of the risk area volume (% infarct size/risk area).

Measurement of myocardium malondialdehyde (MDA) and superoxide dismutase (SOD) activity assay. MDA concentration and SOD activity in myocardial tissue were measured using commercialized assay kits, according to the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute), as described in a previous study (7). MDA concentration was used as an index of oxygen-free radical and SOD activity as the lipid superoxide level in the myocardium.

Immunoblotting analysis. Pulverized frozen ischemia areas of left ventricle samples were analyzed by quantitative immunoblotting using the HMGB1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), as previously described (7). The expression of the protein was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.

Statistical analysis. Statistical analysis was performed with the SPSS 14.0 (SPSS Inc., Chicago, IL, USA). All values were expressed as the means ± SD. The Student's t-test was used for between-group comparisons. One-way ANOVA or Welch was used for comparisons among groups, and the Student-Neuman-Keuls or Dunnett T3 was used for post-hoc multiple comparisons. Statistical significance was defined as p<0.05.

Results

Infarct size. After 4 h of reperfusion, the infarct size induced by myocardial I/R was decreased by GGA pre-treatment compared to that in the I/R group (29.4±4.1 vs. 52.2±4.9%; p<0.05) (Fig. 1).

LDH and CK levels. After 4 h of reperfusion, both LDH and CK levels in the I/R group were significantly increased compared to those in the SO and SO-GGA groups (p<0.05). However, the increasing levels of LDH and CK were significantly attenuated by GGA (both p<0.05) (Fig. 2).

MDA and SOD levels. After 4 h of reperfusion, MDA levels in the I/R group were significantly increased, while SOD levels were significantly decreased compared to those in the SO and SO-GGA groups (p<0.05). Both the increase in MDA levels and the decrease in SOD levels were significantly inhibited by GGA (both p<0.05) (Fig. 3).

Effect of GGA on HMGB1 expression during I/R. As shown in Fig. 4, HMGB1 expression was markedly increased after 4 h of reperfusion (p<0.05), which was significantly inhibited by GGA (p<0.05).

Discussion

The present study demonstrated that GGA is capable of reducing myocardial I/R injury and inhibiting HMGB1 expression. These results indicate that the cardioprotective effect induced by GGA during myocardial I/R injury may be associated with the inhibition of HMGB1 expression.
inhibits the expression of HMGB1 (10,11). We, therefore, speculated that GGA inhibits the expression of HMGB1 by promoting the expression of HSP72.

In the present study, GGA decreased the levels of MDA (one of the reactive oxygen species; ROS) and increased the levels of SOD (a key antioxidant enzyme). Previous studies indicate that ROS may be involved in the release of pro-inflammatory cytokine HMGB1 (12). Tsung et al (14) further demonstrated that the release of HMGB1 from cultured hepatocytes was also found to be an active process regulated by ROS. Recently, Loukili et al (15) showed that peroxy nitrite, a potent cytotoxic oxidant, was involved in the release of HMGB1 in cardiac cells. Hence, inhibiting ROS may cause suppression of HMGB1 expression. In addition, Jiang et al (16) showed that HSP pre-treatment inhibits the apoptosis of the myocardium induced by hydrogen peroxide, which may promote the release of HMGB1. Consequently, these results suggest that GGA, an HSP72 inducer, protects against myocardial I/R injury by inhibiting HMGB1 expression.

Study limitations. In this study, we only observed the effect of GGA on HMGB1 expression during myocardial I/R. However, the precise mechanisms underlying our observations require further elucidation.

In conclusion, the present study suggests that GGA is capable of reducing myocardial I/R injury, which may, possibly, be associated with the inhibition of HMGB1 expression during myocardial I/R.

References


